Unity Biotechnology (UBX) Competitors $1.26 -0.04 (-2.69%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-1.19%) As of 03/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UBX vs. VIRI, EDIT, ADAP, SLN, SGMT, COYA, NKTX, DERM, FATE, and ELUTShould you be buying Unity Biotechnology stock or one of its competitors? The main competitors of Unity Biotechnology include Virios Therapeutics (VIRI), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Silence Therapeutics (SLN), Sagimet Biosciences (SGMT), Coya Therapeutics (COYA), Nkarta (NKTX), Journey Medical (DERM), Fate Therapeutics (FATE), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. Unity Biotechnology vs. Virios Therapeutics Editas Medicine Adaptimmune Therapeutics Silence Therapeutics Sagimet Biosciences Coya Therapeutics Nkarta Journey Medical Fate Therapeutics Elutia Virios Therapeutics (NASDAQ:VIRI) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends. Does the MarketBeat Community prefer VIRI or UBX? Unity Biotechnology received 177 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 67.16% of users gave Unity Biotechnology an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Unity BiotechnologyOutperform Votes18067.16% Underperform Votes8832.84% Which has more risk and volatility, VIRI or UBX? Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Unity Biotechnology has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Is VIRI or UBX more profitable? Unity Biotechnology's return on equity of -119.70% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Unity Biotechnology N/A -119.70%-45.86% Do institutionals and insiders hold more shares of VIRI or UBX? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 29.5% of Unity Biotechnology shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 5.8% of Unity Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend VIRI or UBX? Virios Therapeutics presently has a consensus target price of $3.00, suggesting a potential downside of 53.63%. Unity Biotechnology has a consensus target price of $5.33, suggesting a potential upside of 321.61%. Given Unity Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Unity Biotechnology is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Unity Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer VIRI or UBX? In the previous week, Unity Biotechnology had 12 more articles in the media than Virios Therapeutics. MarketBeat recorded 12 mentions for Unity Biotechnology and 0 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 beat Unity Biotechnology's score of -0.27 indicating that Virios Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Virios Therapeutics Neutral Unity Biotechnology Neutral Which has preferable valuation and earnings, VIRI or UBX? Virios Therapeutics has higher earnings, but lower revenue than Unity Biotechnology. Virios Therapeutics is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-23.96Unity Biotechnology$240K88.91-$39.86M-$1.53-0.83 SummaryUnity Biotechnology beats Virios Therapeutics on 11 of the 16 factors compared between the two stocks. Remove Ads Get Unity Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UBX vs. The Competition Export to ExcelMetricUnity BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.34M$6.99B$5.68B$8.30BDividend YieldN/A2.73%4.55%4.02%P/E Ratio-0.977.2324.5819.25Price / Sales88.91232.30388.1194.32Price / CashN/A65.6738.1634.64Price / Book0.756.617.074.46Net Income-$39.86M$142.13M$3.19B$247.07M7 Day Performance-29.33%-1.51%-0.92%0.14%1 Month Performance-26.45%-3.46%3.58%-4.39%1 Year Performance-21.91%-5.32%14.15%4.85% Unity Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UBXUnity Biotechnology4.2183 of 5 stars$1.27-2.7%$5.33+321.6%-19.9%$21.34M$240,000.00-0.9760Analyst ForecastNews CoverageVIRIVirios Therapeutics0.2479 of 5 stars$6.12-20.8%$3.00-51.0%+1,306.5%$117.86MN/A-22.675Gap UpEDITEditas Medicine4.1826 of 5 stars$1.41-3.4%$6.83+384.6%-82.3%$117.00M$32.31M-0.55230Positive NewsGap DownADAPAdaptimmune Therapeutics2.18 of 5 stars$0.46+1.4%$2.79+510.4%-82.6%$116.86M$175.04M-2.08490Earnings ReportNews CoverageSLNSilence Therapeutics2.7841 of 5 stars$3.90-0.3%$40.67+942.7%-83.4%$116.73M$43.26M-2.48100Positive NewsGap DownSGMTSagimet Biosciences2.4591 of 5 stars$3.78+1.1%$23.00+508.5%-22.8%$115.95M$2M-2.648COYACoya Therapeutics2.1807 of 5 stars$6.85+5.5%$16.25+137.2%-26.1%$114.44M$9.55M-10.546NKTXNkarta2.2244 of 5 stars$1.62-2.4%$15.00+825.9%-86.4%$114.32MN/A-0.86140Upcoming EarningsDERMJourney Medical2.5877 of 5 stars$5.31+1.1%$9.67+82.0%+121.9%$110.93M$57.77M-5.6590FATEFate Therapeutics3.9485 of 5 stars$0.97+2.6%$5.50+469.2%-86.9%$110.74M$13.63M-0.59550Positive NewsELUTElutia4.0625 of 5 stars$3.20+0.6%$9.00+181.3%-16.2%$110.60M$24.38M-1.23180 Remove Ads Related Companies and Tools Related Companies Virios Therapeutics Competitors Editas Medicine Competitors Adaptimmune Therapeutics Competitors Silence Therapeutics Competitors Sagimet Biosciences Competitors Coya Therapeutics Competitors Nkarta Competitors Journey Medical Competitors Fate Therapeutics Competitors Elutia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UBX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unity Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unity Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UBX Stock Free UBX Stock Alerts